

Correction

Correction: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus

Fatih M Uckun*¹, Alexander S Petkevich², Alexei O Vassilev¹,
Heather E Tibbles¹ and Leonid Titov²

Address: ¹Parker Hughes Center for Clinical Immunology, St. Paul, MN 55113, USA and ²Research Institute for Epidemiology and Microbiology, 220050 MINSK, Belarus

Email: Fatih M Uckun* - fatih_uckun@ih.org; Alexander S Petkevich - asp@briem.ac.by; Alexei O Vassilev - avassilev@ih.org;
Heather E Tibbles - htibbles@ih.org; Leonid Titov - briem@hmti.ac.by

* Corresponding author

Published: 01 June 2004

BMC Infectious Diseases 2004, 4:14

This article is available from: <http://www.biomedcentral.com/1471-2334/4/14>

Received: 01 June 2004

Accepted: 01 June 2004

© 2004 Uckun et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Text

In our recent article [1], we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:

FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.

References

1. Uckun FU, Petkevich AS, Vassilev AO, Tibbles HE, Titov LP: **Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus.** *BMC Infect Dis* 2004, 4:1.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2334/4/14/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

